473 related articles for article (PubMed ID: 31786560)
1. Vascular architecture mapping for early detection of glioblastoma recurrence.
Stadlbauer A; Eyüpoglu I; Buchfelder M; Dörfler A; Zimmermann M; Heinz G; Oberndorfer S
Neurosurg Focus; 2019 Dec; 47(6):E14. PubMed ID: 31786560
[TBL] [Abstract][Full Text] [Related]
2. Physiological MRI of microvascular architecture, neovascularization activity, and oxygen metabolism facilitate early recurrence detection in patients with IDH-mutant WHO grade 3 glioma.
Stadlbauer A; Heinz G; Oberndorfer S; Zimmermann M; Kinfe TM; Buchfelder M; Dörfler A; Kremenevski N; Marhold F
Neuroradiology; 2022 Feb; 64(2):265-277. PubMed ID: 34115146
[TBL] [Abstract][Full Text] [Related]
3. Vascular Hysteresis Loops and Vascular Architecture Mapping in Patients with Glioblastoma treated with Antiangiogenic Therapy.
Stadlbauer A; Zimmermann M; Oberndorfer S; Doerfler A; Buchfelder M; Heinz G; Roessler K
Sci Rep; 2017 Aug; 7(1):8508. PubMed ID: 28819189
[TBL] [Abstract][Full Text] [Related]
4. Role of FDG-PET/MRI, FDG-PET/CT, and Dynamic Susceptibility Contrast Perfusion MRI in Differentiating Radiation Necrosis from Tumor Recurrence in Glioblastomas.
Hojjati M; Badve C; Garg V; Tatsuoka C; Rogers L; Sloan A; Faulhaber P; Ros PR; Wolansky LJ
J Neuroimaging; 2018 Jan; 28(1):118-125. PubMed ID: 28718993
[TBL] [Abstract][Full Text] [Related]
5. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.
Kim JY; Park JE; Jo Y; Shim WH; Nam SJ; Kim JH; Yoo RE; Choi SH; Kim HS
Neuro Oncol; 2019 Feb; 21(3):404-414. PubMed ID: 30107606
[TBL] [Abstract][Full Text] [Related]
6. Physiological MRI Biomarkers in the Differentiation Between Glioblastomas and Solitary Brain Metastases.
Heynold E; Zimmermann M; Hore N; Buchfelder M; Doerfler A; Stadlbauer A; Kremenevski N
Mol Imaging Biol; 2021 Oct; 23(5):787-795. PubMed ID: 33891264
[TBL] [Abstract][Full Text] [Related]
7. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
[TBL] [Abstract][Full Text] [Related]
8. Development of a Non-invasive Assessment of Hypoxia and Neovascularization with Magnetic Resonance Imaging in Benign and Malignant Breast Tumors: Initial Results.
Stadlbauer A; Zimmermann M; Bennani-Baiti B; Helbich TH; Baltzer P; Clauser P; Kapetas P; Bago-Horvath Z; Pinker K
Mol Imaging Biol; 2019 Aug; 21(4):758-770. PubMed ID: 30478507
[TBL] [Abstract][Full Text] [Related]
9. Tissue Hypoxia and Alterations in Microvascular Architecture Predict Glioblastoma Recurrence in Humans.
Stadlbauer A; Kinfe TM; Eyüpoglu I; Zimmermann M; Kitzwögerer M; Podar K; Buchfelder M; Heinz G; Oberndorfer S; Marhold F
Clin Cancer Res; 2021 Mar; 27(6):1641-1649. PubMed ID: 33293375
[TBL] [Abstract][Full Text] [Related]
10. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
[TBL] [Abstract][Full Text] [Related]
11. Physiologic MR imaging of the tumor microenvironment revealed switching of metabolic phenotype upon recurrence of glioblastoma in humans.
Stadlbauer A; Oberndorfer S; Zimmermann M; Renner B; Buchfelder M; Heinz G; Doerfler A; Kleindienst A; Roessler K
J Cereb Blood Flow Metab; 2020 Mar; 40(3):528-538. PubMed ID: 30732550
[TBL] [Abstract][Full Text] [Related]
12. Perfusion MRI in the Evaluation of Suspected Glioblastoma Recurrence.
Blasel S; Zagorcic A; Jurcoane A; Bähr O; Wagner M; Harter PN; Hattingen E
J Neuroimaging; 2016; 26(1):116-23. PubMed ID: 25907688
[TBL] [Abstract][Full Text] [Related]
13. High-resolution blood-pool-contrast-enhanced MR angiography in glioblastoma: tumor-associated neovascularization as a biomarker for patient survival. A preliminary study.
Puig J; Blasco G; Daunis-I-Estadella J; Alberich-Bayarri A; Essig M; Jain R; Remollo S; Hernández D; Puigdemont M; Sánchez-González J; Mateu G; Wintermark M; Pedraza S
Neuroradiology; 2016 Jan; 58(1):17-26. PubMed ID: 26438560
[TBL] [Abstract][Full Text] [Related]
14. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
[TBL] [Abstract][Full Text] [Related]
15. Dynamic susceptibility contrast (DSC) perfusion MRI in differential diagnosis between radionecrosis and neoangiogenesis in cerebral metastases using rCBV, rCBF and K2.
Muto M; Frauenfelder G; Senese R; Zeccolini F; Schena E; Giurazza F; Jäger HR
Radiol Med; 2018 Jul; 123(7):545-552. PubMed ID: 29508242
[TBL] [Abstract][Full Text] [Related]
16. Baseline multicentric tumors, distant recurrences and leptomeningeal dissemination predict poor survival in patients with recurrent glioblastomas receiving bevacizumab.
Toh CH; Liau CT; Wei KC; Castillo M
J Neurooncol; 2019 Mar; 142(1):149-159. PubMed ID: 30535596
[TBL] [Abstract][Full Text] [Related]
17. Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility.
Kim HS; Goh MJ; Kim N; Choi CG; Kim SJ; Kim JH
Radiology; 2014 Dec; 273(3):831-43. PubMed ID: 24885857
[TBL] [Abstract][Full Text] [Related]
18. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
[TBL] [Abstract][Full Text] [Related]
19. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
[TBL] [Abstract][Full Text] [Related]
20. Recurrent pseudoprogression in isocitrate dehydrogenase 1 mutant glioblastoma.
Kebir S; Rauschenbach L; Gielen GH; Schäfer N; Tzaridis T; Scheffler B; Giordano FA; Lazaridis L; Herrlinger U; Glas M
J Clin Neurosci; 2018 Jul; 53():255-258. PubMed ID: 29754968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
